Lawsuit filed for Investors in shares of ChemoCentryx, Inc. (NASDAQ: CCXI)

An investor, who purchased shares of ChemoCentryx, Inc. (NASDAQ: CCXI), filed a lawsuit over alleged violations of Federal Securities Laws by ChemoCentryx, Inc.

Investors who purchased shares of ChemoCentryx, Inc. (NASDAQ: CCXI) have certain options and for certain investors are short and strict deadlines running. Deadline: July 6, 2021. NASDAQ: CCXI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Mountain View, CA based ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.

On May 4, 2021, the U.S. Food and Drug Administration released a "Briefing Document" concerning ChemoCentryx's drug candidate avacopan, which is in development for the treatment of adult patients with anti-neutrophil cytoplasmic autoantibody vasculitis. In this Briefing Document, the FDA wrote that its review team "has identified several areas of concern, raising uncertainties about the interpretability of the data" submitted as part of ChemoCentryx's application, as well as concerns with "the clinical meaningfulness of these results."

ChemoCentryx, Inc. (NASDAQ: CCXI) declined to as low as $9.55 per share on May 7, 2021.

The plaintiff claims that between November 26, 2019 and May 3, 2021, the defendants made false and/or misleading statements and/or failed to disclose that the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis, that the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan, that these issues presented a substantial concern regarding the viability of ChemoCentryx's NDA for avacopan for the treatment of ANCA-associated vasculitis, and that as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Those who purchased shares of ChemoCentryx, Inc. (NASDAQ: CCXI) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.